Cite

    Rensel, M., Zabeti, A., Mealy, M. A., Cimbora, D., She, D., Drappa, J., & Katz, E. (2022). long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Multiple sclerosis, 28, 925–932. http://access.bl.uk/ark:/81055/vdc_100147707853.0x000021